CATX AMEX
Credit Risk of going bust: higher than 66% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.4%), Perspective Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.0M against a stock market value of $138.1M.
Distance to default 3.75 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.9M (short-term plus half of long-term), stock volatility 103.0%; Altman Z -0.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Seattle, WA 98121
US
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle â from development and manufacturing to sales and marketing â of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lantheus Alpha Thera | S-Sale | 167,149 | $3.15 | 2026-09-04 |
| Lantheus Alpha Thera | S-Sale | 80,783 | $3.11 | 2026-09-03 |
| Lantheus Alpha Thera | S-Sale | 42,129 | $3.11 | 2026-09-02 |
| Lantheus Alpha Thera | S-Sale | 35,769 | $3.12 | 2026-09-01 |
| Lantheus Holdings, I | S-Sale | 35,769 | $3.12 | 2026-09-01 |